Skip to main content
Premium Trial:

Request an Annual Quote

MolecularMD to Provide qRT-PCR Patient Monitoring for CML Alliance

NEW YORK (GenomeWeb News) - MolecularMD said today it is providing qRT-PCR-based patient monitoring for the CML Alliance, a Novartis-run program that aims to improve outcomes for patients with Philadelphia Chromosome Positive Chronic Myelogenous Leukemia.
The Novartis drug Gleevec, or imatinib, is a kinase inhibitor that targets the BCR-ABL protein to treat CML. In clinical studies, patients prescribed Gleevec who achieve major molecular response as measured by qRT-PCR have the best five-year prognosis for progression-free survival, MolecularMD said.
MolecularMD’s test monitors BCR-ABL oncogene expression by qRT-PCR.
“Results provided by our lab will enable patients and their healthcare providers to confidently optimize treatment of CML,” said MolecularMD’s scientific founder Brian Druker.
Genzyme Genetics is also offering PCR-based BCR-ABL monitoring as part of the CML Alliance.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.